ERBB2 and breast cancer: Triple-negative breast cancer (TNBC), responsible for around 15% of global breast cancer (BC) cases, is histopathologically featured by shortages of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER)-2 [1].